Genetic ablation of Arg1 in macrophages or blocking ARG1 in vivo can restrain tumor growth and boost the anti-tumor efficacy of adoptive cell transfer (ACT) therapy in EG7 lymphoma and 3LL lung carcinoma in mice (Rodriguez et al., 2004; Marigo et al., 2016). Here, ARG1 is linked to lymphoma.